Obinutuzumab
Generic Details
Generic Name
Obinutuzumab
Other Names
- Gazyva
Drug Class
- Monoclonal antibody
Chemical Formula
C6506H10058N1734O2028S42
Molecular Weight
145.7 kDa
Mechanism of Action
- Binds to CD20 antigen on B-cells, leading to cell death via antibody-dependent cellular cytotoxicity
Indications
- Chronic lymphocytic leukemia (CLL)
- Follicular lymphoma
Common Dosage Forms
- Injection
Typical Dosage
- 1000 mg on day 1, 1000 mg on day 8, then 1000 mg every 28 days for up to 6 cycles
Pediatric Dosage
- Safety and efficacy not established in children
Geriatric Dosage
- Dosage adjustment may be necessary based on individual patient factors
Side Effects
- Infusion reactions
- Neutropenia
- Thrombocytopenia
- Fatigue
- Nausea
- Diarrhea
Contraindications
- Hypersensitivity to obinutuzumab
- Active infections
Pregnancy Category
- Category C - Risk cannot be ruled out
Lactation Safety
- Unknown if excreted in breast milk, consult healthcare provider
Drug Interactions
- Live vaccines
- Immunosuppressive agents
Overdose Symptoms
- Increased risk of infections
- Hepatic and renal impairment
Antidote for Overdose
- No specific antidote, manage symptoms and provide supportive care
Storage Conditions
- Refrigerate at 2°C to 8°C (36°F to 46°F), do not freeze
Pharmacokinetics
- Absorption: Bioavailability is not applicable as it is administered intravenously
- Distribution: Highly protein-bound
- Metabolism: Metabolic pathway not fully elucidated
- Excretion: Mainly through reticuloendothelial system and kidneys
Precautions
- Monitor for signs of infections during treatment
- Hepatic and renal function tests
Warnings
- Infusion reactions can occur, administer in a healthcare setting with monitoring
Others
- Regular blood cell counts recommended during treatment